A Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics and Safety of VIR-2218

Renal Impairment Clinical Trial

Official title:

A Phase 1, Open-Label, Single-Dose, Parallel-Group Study of the Pharmacokinetics and Safety of VIR-2218 in Adult Participants With Renal Impairment

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05844228
• Other study ID #: VIR-2218-V108
• Status: Recruiting
• Phase: Phase 1
• Start date: June 1, 2023
• Est. completion date: November 21, 2025

Study information

• Verified date: May 2024
• Source: Vir Biotechnology, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The rationale of this study is to evaluate the impact of renal function on the PK, safety, and tolerability of VIR-2218 in participants with normal renal function and participants with varying degrees of renal dysfunction who are otherwise medically stable

Description:

Participants may be enrolled in Cohorts 1 and 2 in a non-randomized way.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 32
• Est. completion date: November 21, 2025
• Est. primary completion date: May 15, 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria for All Participants:

• Participants must have stable renal function as defined by less than 20% change in estimated glomerular filtration rate (eGFR) between the first and second screening sample with the first screening visit occurring within 28 days prior to dosing on Day 1 and the second screening visit occurring no more than 14 days apart, but at least 72 hours apart from the first.
• Body mass index (BMI) within the range 18.5 to 35.0 kg/m2 at screening.
• Female and Male participants must consent to follow contraception requirements
• Capability of giving signed informed consent form

Inclusion Criteria: Additional Criteria Specific to Healthy Participants:

• Must be in the opinion of the investigator, be in good health based upon medical history, vital signs, physical examination, and screening laboratory evaluations
• Must have normal renal function as defined by eGFR = 90 mL/min/1.73m2 based on the Modification of Diet in Renal Disease (MDRD) equation determined from the mean of two measurements of serum creatinine at screening. Inclusion Criteria: Additional Criteria Specific to Participants with Renal Impairment
• Participants must, in the opinion of the investigator, be sufficiently healthy for study participation based on medical history, physical examination, vital signs, and screening laboratory evaluations
• Participants with RI must have chronic moderate or severe RI and be clinically stable per investigator assessment for at least 3 months prior to screening
• Moderate RI as defined by eGFR level 30-59 mL/min/1.73m2 based on the MDRD equation, or
• Severe RI as defined by eGFR level 15-29 mL/min/1.73m2 based on the MDRD equation Exclusion Criteria: Criteria for All Participants
• Any clinically significant medical condition or psychiatric condition that may interfere with study intervention
• Participants with uncontrolled hypertension, asthma, and/or diabetes (Type I or II).
• Participants with diabetes
• Participants with any active malignancy
• Participants with vasculitis or conditions associated with vasculitis.
• Participants who have undergone major surgery within 12 months of screening
• Participants with unstable cardiac functions, abnormality, or clinically significant heart failure
• Participants with infection of HIV, HAV, HBV, HCV, HDV, or HEV
• Participants with signs of active infection
• History of bone marrow or solid organ transplantation
• Participants with end-stage renal disease or nephrotic syndrome as defined by:

participants requiring hemodialysis or peritoneal dialysis, participants who have undergone or are listed for transplant, or participants who have chronic kidney disease with nephrotic syndrome

• Participants with active nephritis
• Participants with clinically significant liver disease
• History of drug or alcohol abuse
• Unwillingness or inability to follow procedures outlined in protocol Exclusion Criteria: Additional Criteria Specific to Healthy Participants
• Use of any prescription medications or over-the-counter medications (with the exception of vitamins and/or hormonal contraceptive medications) including herbal products within 30 days prior to D1 of study participation Exclusion Criteria: Additional Criteria Specific to Participants with Renal Impairment
• Not on stable dose and regimen of any medication(s) (prescription or over-the-counter) that the participants is taking regularly (eg, medications for chronic conditions such as hypertension, high cholesterol, or depression must not be changed in dose or type for at least 2 weeks prior to study drug administration)

Related Conditions & MeSH terms

• Renal Impairment
• Renal Insufficiency

Intervention

Drug:
• VIR-2218
VIR-2218 given by subcutaneous injection

Locations

Country	Name	City	State
United States	Floridian Clinical Research	Miami Lakes	Florida
United States	Orlando Clinical Research Center	Orlando	Florida
United States	Inland Empire Clinical Trials	Rialto	California

Sponsors (1)

Lead Sponsor	Collaborator
Vir Biotechnology, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum Observed Plasma Concentration (Cmax) of VIR-2218 and its metabolite AS(N-1)3'VIR-2218		5 days
Primary	Area Under The Plasma Concentration-time Curve from Time Zero to Time of Last Quantifiable Concentration (AUClast) of VIR-2218 and metabolite AS(N-1)3'VIR-2218		5 days
Primary	Area Under the Plasma Concentration-time Curve from Time Zero to Infinity (AUCinf) of VIR-2218 metabolite AS(N-1)3'VIR-2218		5 days
Primary	Fraction excreted in urine in percentage for VIR-2218 and its metabolite AS(N-1)3'VIR-2218		5 days
Primary	Amount excreted in urine for VIR-2218 and its metabolite AS(N-1)3'VIR-2218		5 days
Primary	Renal clearance for VIR-2218 and its metabolite AS(N-1)3'VIR-2218		5 days
Secondary	Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)		8 weeks